

Table 1 Supplementary Materials. Results on efficacy parameters evaluated during the study.

	Dose rhNGF eye drop	Baseline (from day-15 to day -1)	Day 1	Day 8±1	Day 29±1 (end of treatment)	Day 56±4 (end of follow-up)
Frequency of DED symptoms (SANDE scale) (mean±SD)	20 µg/ml	55.3±27.3	47.3±24.2*	40.3±23.1*	28.4±26.2*	25.2±26.5*
	4 µg/ml	59.7±29.2	49.7±22.4	36.4±23.8*	33.5±26.4*	31.7±26.8*
Severity of DED symptoms (SANDE scale) (mean±SD)	20 µg/ml	52.8±23.2	45.3±23.7	41.1±23.1*	25.9±26.9*	23.9±28.1*
	4 µg/ml	60.1±29.6	50.3±21.6	39.1±27.0*	31.5±25.5*	31.9±27.9*
OSDI scale (mean±SD)	20 µg/ml	55.52 ±21.81	50.15±22.37*	41.19±21.34 *	32.6±16.2*	32.05±21.4 2*
	4 µg/ml	52.48±21.84	52.26±21.66	42.09±23.57 *	35.77±22.82 *	37.72±20.1 4*
NEI ocular surface total score (mean±SD)	20 µg/ml	13.3±4.9	11.8±3.5	7.4±2.8*	3.8±3.1*	5.5±3.2*
	4 µg/ml	12.6±5.1	12.9±5.4	10.4±5.5*	7.5±4.8*	7.7±5.3*
NEI cornea total score (mean±SD)	20 µg/ml	5.2±2.0	4.8±2.0	2.5±1.6*	1.3±2.2*	1.2±1.6*
	4 µg/ml	5.9±2.7	5.7±2.9	4.7±3.5*	3.0±3.3*	3.1±2.9*
NEI conjunctiva total score (mean±SD)	20 µg/ml	8.1±3.5	7.0±2.5*	4.9±2.2*	2.5±1.4*	4.3±2.0*
	4 µg/ml	6.8±2.7	7.3±3.0	5.7±2.6*	4.5±2.1*	4.6±2.9*
Cornea sensitivity Cochet-Bonnet esthesiometer mm (mean±SD)	20 µg/ml	5.6±0.91	5.65±0.54	5.63±0.72	5.93±0.18	5.88±0.39*
	4 µg/ml	5.43±1.2	5.63±0.99	5.8±0.44	5.79±0.71	5.93±0.18*
Schirmer test I mm/5 minutes (mean±SD)	20 µg/ml	4.1±3.3	5.4±5.7	8.6±9.0*	9.4±7.8*	8.7±10.2*
	4 µg/ml	5.2±3.7	6.5±6.7	5.9±6.8	8.2±6.8	9.8±8.8*
Break-up time Seconds (mean±SD)	20 µg/ml	3.4±2	4±1.8	4.9±2.2*	6.0±2.5*	5.6±2.4*
	4 µg/ml	3±2.4	2.3±2.1	2.7±1.7	2.5±1.3	2.7±2.1

Tear osmolarity (Tear Lab)	20 µg/ml	313.6 ±13.7	304.6±9.1*	309.6±11.9	308.2±12.3*	308.8±9.8
mOsm/L (mean±SD)	4 µg/ml	313.6 ±16.1	313.2±16.8	314.4±19.2	312.5±12.3	318±18.3

OSDI: Ocular Surface Disease Index; NEI: National Eye Institute; mm: millimeters

*p<0.05 Wilcoxon signed-rank test